{"nctId":"NCT00223977","briefTitle":"2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.","startDateStruct":{"date":"2003-12"},"conditions":["Iron Deficiency Anemia"],"count":146,"armGroups":[{"label":"Sodium ferric gluconate complex 125 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Sodium Ferric Gluconate Complex"]},{"label":"Sodium ferric gluconate complex 250 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Sodium Ferric Gluconate Complex"]},{"label":"Oral iron","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Oral Iron"]}],"interventions":[{"name":"Sodium Ferric Gluconate Complex","otherNames":["Ferrlecit"]},{"name":"Sodium Ferric Gluconate Complex","otherNames":["Ferrlecit"]},{"name":"Oral Iron","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female, at least 18 years of age.\n* Received maintenance peritoneal dialysis therapy for at least 4 weeks.\n* Was expected to remain on peritoneal dialysis therapy for duration of study.\n* Had predetermined low hemoglobin and transferrin saturation (TSAT) levels.\n* Signed patient informed consent.\n\nExclusion Criteria:\n\n* Had a predetermined serum levels of Ferritin and TSAT\n* Pregnant or lactating.\n* Had a serious concomitant medical disorder incompatible with participation in the study.\n* Had a known hypersensitivity to Ferrlecit or any of its components.\n* Unable to cooperate or comply with the protocol.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Hemoglobin","description":"Change from baseline to 1 week after the last oral iron dose or 2 weeks after the last sodium ferric gluconate injection","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.49","spread":"1.09"},{"groupId":"OG001","value":"0.89","spread":"1.35"},{"groupId":"OG002","value":"1.02","spread":"1.55"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Hematocrit (Hct)","description":"Change from baseline to 1 week after the last oral iron dose or 2 weeks after the last sodium ferric gluconate injection","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.62","spread":"3.37"},{"groupId":"OG001","value":"2.93","spread":"4.61"},{"groupId":"OG002","value":"3.07","spread":"4.59"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Transferrin Saturation (TSAT).","description":"Change from baseline to 1 week after the last oral iron dose or 2 weeks after the last sodium ferric gluconate injection","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.13","spread":"8.77"},{"groupId":"OG001","value":"8.2","spread":"9.31"},{"groupId":"OG002","value":"1.84","spread":"6.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serum Ferritin.","description":"Change from baseline to 1 week after the last oral iron dose or 2 weeks after the last sodium ferric gluconate injection","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"259.88","spread":"212.73"},{"groupId":"OG001","value":"368.67","spread":"270.05"},{"groupId":"OG002","value":"26.98","spread":"86.57"}]}]}]},{"type":"SECONDARY","title":"Responders by Treatment Group","description":"Patients were classified as responders to treatment if they had an increase in Hgb of at least 1.0 g/dL assessed at 2 weeks following the final administration of Ferrlecit or 1 week following the last dose of oral iron.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"20","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":46},"commonTop":["LAB TEST ABNORM","HYPERTENS","DIARRHEA","INFECT","PAIN ABDO"]}}}